Robin Swartz Sells 6,500 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Voyager Therapeutics Stock Down 2.9 %

Shares of VYGR opened at $5.74 on Friday. The stock has a market cap of $313.55 million, a P/E ratio of 8.08 and a beta of 0.90. The business’s 50 day moving average price is $6.35 and its 200-day moving average price is $7.01. Voyager Therapeutics, Inc. has a 52 week low of $5.19 and a 52 week high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. During the same period in the previous year, the company posted ($0.59) earnings per share. On average, equities analysts anticipate that Voyager Therapeutics, Inc. will post -0.89 EPS for the current year.

Institutional Trading of Voyager Therapeutics

Several institutional investors have recently bought and sold shares of VYGR. SG Americas Securities LLC purchased a new position in Voyager Therapeutics in the second quarter worth about $85,000. Bank of New York Mellon Corp raised its holdings in Voyager Therapeutics by 17.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 294,420 shares of the company’s stock worth $2,329,000 after acquiring an additional 44,289 shares during the last quarter. Commonwealth Equity Services LLC lifted its position in Voyager Therapeutics by 36.8% in the 2nd quarter. Commonwealth Equity Services LLC now owns 77,905 shares of the company’s stock valued at $616,000 after acquiring an additional 20,950 shares in the last quarter. Rhumbline Advisers boosted its stake in Voyager Therapeutics by 56.0% during the 2nd quarter. Rhumbline Advisers now owns 72,461 shares of the company’s stock valued at $573,000 after purchasing an additional 26,014 shares during the last quarter. Finally, Victory Capital Management Inc. increased its holdings in shares of Voyager Therapeutics by 14.5% in the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after purchasing an additional 1,630 shares in the last quarter. 48.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on VYGR. Leerink Partners assumed coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price on the stock. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Wedbush started coverage on shares of Voyager Therapeutics in a research note on Friday, November 29th. They set an “outperform” rating and a $11.00 target price on the stock. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $17.00.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.